ott166
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 29, 2022 (NCT05409235)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Vitronectin receptor alphaINHIBITOR
ITGAV inhibitor
Fibronectin receptor (Integrin alpha-5/beta-1 and alpha-V/beta-3) inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05409235 | Phase 2 | Jul 29, 2022 | OcuTerra Therapeutics, Inc., Parexel |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| OcuTerra Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2022 |
| Parexel | For profit | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1